CLLS - Cellectis S.A.
Cellectis S.A.
8, rue de la Croix Jarry
Paris 75013
France
33 1 81 69 16 00
https://www.cellectis.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 231
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Dr. Andre Choulika Ph.D. | Co-Founder, CEO & Director | 744.02k | N/A | 1965 |
| Dr. David J. D. Sourdive Ph.D. | Deputy CEO, Exec. VP of CMC & Manufacturing and Directorr | 528.92k | N/A | 1967 |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer | N/A | N/A | 1977 |
| Valerie Cros | Principal Financial Officer & Principal Accounting Officer | N/A | N/A | N/A |
| Mr. Jean Charles Epinat | Chief Technological Officer | N/A | N/A | N/A |
| Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer | N/A | N/A | 1963 |
| Mr. Stephan Reynier M.Sc., MSc | Chief Regulatory & Pharmaceutical Compliance Officer | N/A | N/A | 1969 |
| Ms. Marie-Bleuenn Terrier | Gen. Counsel & Sec. of the Board of Directors | N/A | N/A | 1982 |
| Pascalyne Wilson | Director of Communications | N/A | N/A | N/A |
| Ms. Kyung Nam-Wortman | Exec. VP & Chief HR Officer | N/A | N/A | 1970 |
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Corporate governance
Cellectis S.A.’s ISS governance QualityScore as of 30 May 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 10; Compensation: 8.
